The Israel Cancer Research Fund (ICRF), which supports cancer research at Weizmann, shares the story of Jewish hockey player Sam Fields, who was felled by aggressive CML just before turning pro. His life was saved, thanks to Gleevec, for which the Institute’s Prof. Eli Canaani helped lay the foundation.
March 08, 2017
Prof. Yosef Yarden, “among the most important cancer researchers in the world,” is receiving the 2017 Israel Prize in Life Science Research. Prof. Yarden discovered the function of an enzyme that leads to cancer, a finding that laid the foundation for the development of new cancer treatments. The Israel Prize is considered the country’s highest honor.
March 02, 2017
As Britain's Royal Pharmaceutical Society reports in its Pharmaceutical Journal, researchers working on T-cell therapies for cancer – such as Weizmann's Prof. Zelig Eshhar – were snubbed for years… until now. This thorough overview of the field's beginning – including in Prof. Eshhar's lab – and its future makes clear the importance of T cells.
August 24, 2016
Prof. Zelig Eshhar, whose basic research led to the creation of cancer-killing T-cells, is one of six scientists to receive a 2016 Novartis Prize for Immunology. Announced and granted by the healthcare and pharma company, the prestigious prizes are ""awarded every three years for breakthrough contributions to the fields of basic and clinical immunology.""
August 15, 2016
Two Weizmann PhDs are behind Nucleix, an Israeli company that has designed a simple test for monitoring bladder cancer – the most expensive cancer to treat over a patient's lifetime. Called ""Bladder EpiCheck,"" the method is in advanced clinical trials in The Netherlands, Germany, Spain, and Israel, reports Israel21c – and is heading for the U.S.
June 20, 2016
It takes a village to bring a new treatment to market – and in the case of the prostate cancer therapy developed by Profs. Avigdor Scherz and Yoram Salomon, that village includes Steba Biotech, which said ""We looked at the technology for ten minutes and said, ‘We'll take it'."" Globes interviews the father and son behind the Israel-based pharmaceutical house.
June 06, 2016
Tookad, the prostate cancer treatment developed by Profs. Avigdor Scherz and Yoram Salomon, ""now is undergoing advanced trials in Israel and Europe,"" says Israel21c. Already approved for use in Mexico and on the verge of being more widely available, Tookad's efficacy for other cancers is now being tested in collaboration with Oxford University and Memorial Sloan Kettering.
April 11, 2016
As The Times of Israel reports, ""In a trial, a photosynthesis-based therapy eliminates cancer in over 80% of patients – and could be used to attack other cancers, too."" That therapy – developed at the Weizmann Institute – involves administering a drug, then zapping it with light, basically starving the tumor to death … and all without side effects.
April 03, 2016
U.S. scientists have treated blood cancer patients with genetically modified T-cells, and, in what is called an extraordinary development, saw the disease go into remission. As The Times of Israel reports, this true breakthrough began in the lab of Prof. Zelig Eshhar, who created the basis of the technique and has been curing mice of cancer for years.
February 17, 2016